Tag Archive for: CNS drug development

Rewind Therapeutics Secures Additional Financing to Advance Oral GPR17 Remyelination Program

/in

Financing will be used to advance Rewind’s lead oral program designed to promote remyelination and restore neurological function Peer-reviewed data published in PLOS ONE demonstrated remyelination and functional recovery following oral treatment with a selective GPR17 antagonist in preclinical models Leuven, Belgium – 6 October 2026 – Rewind Therapeutics (“Rewind”), a biotechnology company developing small-molecule […]

Read more

CONNECTA Therapeutics and Centre for Genomic Regulation to Present First-in-Class Program CTH120 for Fragile X Syndrome at FENS Forum 2026

/in

Preclinical data highlight restoration of cognitive, behavioral and synaptic deficits in Fragile X syndrome models Barcelona, Spain – 2 July 2026 – CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address unmet medical needs in central nervous system (CNS) disorders, today announced that it will present a poster, together with the Centre […]

Read more

CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome

/in

Builds on positive Phase I safety data and represents a key value-inflection milestone for the Company Advances a potentially disease-modifying approach for fragile X syndrome, a condition with no approved targeted therapies Barcelona, Spain – 10 June 2026 – CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address unmet medical needs in […]

Read more

FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate

/in

Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals Appointment strengthens confidence in clinical readiness and execution as the Company progresses toward first-in-human development Heidelberg, Germany – 2 June 2026 – FundaMental Pharma GmbH (or “the Company”), a preclinical-stage biopharmaceutical company focused on developing innovative, dual-acting N-methyl-D-aspartate […]

Read more
© Optimum Strategic Communications.